LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD)
Clinical trials for LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD) explained in plain language.
Never miss a new study
Get alerted when new LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD) trials appear
Sign up with your email to follow new studies for LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New oil may cut Life-Threatening events in kids with rare fat disorder
Disease control OngoingThis study compares triheptanoin, a special oil, to standard MCT oil in 69 children (newborn to under 18) with long-chain fatty acid oxidation disorders (LC-FAOD), a rare condition where the body can't break down certain fats for energy. The goal is to see if triheptanoin reduces…
Matched conditions: LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD)
Phase: PHASE3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated May 13, 2026 16:08 UTC
-
New study tracks Long-Term safety of rare disease treatment
Disease control OngoingThis study follows 150 people with long-chain fatty acid oxidation disorders (LC-FAOD) to monitor the long-term safety of the drug triheptanoin. Researchers will track serious side effects, pregnancy outcomes, and infant health. The goal is to understand how well the treatment wo…
Matched conditions: LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD)
Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated May 13, 2026 16:00 UTC